Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report

Alì,Greta; Chella,Antonio; Lupi,Cristiana; Proietti,Agnese; Niccoli,Cristina; Boldrini,Laura; Davini,Federico; Mussi,Alfredo; Fontanini,Gabriella

doi:10.3892/ol.2015.2897

April-2015 Volume 9 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

April-2015 Volume 9 Issue 4

Full Size Image

Case Report Open Access

Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report

Authors:
- Greta Alì
- Antonio Chella
- Cristiana Lupi
- Agnese Proietti
- Cristina Niccoli
- Laura Boldrini
- Federico Davini
- Alfredo Mussi
- Gabriella Fontanini
View Affiliations / Copyright

Affiliations: Department of Pathological Anatomy, Azienda Ospedaliera Universitaria Pisana, Pisa, Tuscany I‑56126, Italy, Department of Pneumology, Azienda Ospedaliera Universitaria Pisana, Pisa, Tuscany I‑56126, Italy, Department of Surgical, Medical, Molecular Pathology and Critical Care, Division of Pathological Anatomy, University of Pisa, Pisa, Tuscany I‑56126, Italy, Unit of Thoracic Surgery, Azienda Ospedaliera Universitaria Pisana, Pisa, Tuscany I‑56126, Italy, Department of Surgical, Medical, Molecular Pathology and Critical Care, Division of Thoracic Surgery, University of Pisa, Pisa, Tuscany I‑56126, Italy

Copyright: © Alì et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 1537-1540
|
Published online on: January 26, 2015

https://doi.org/10.3892/ol.2015.2897
Expand metrics +

Abstract

Lung cancer is the leading cause of cancer‑associated mortality worldwide, and the mainstay of treatment remains to be personalised therapy. Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR‑TKIs) have been reported to exert a significant impact in the treatment of non‑small cell lung cancer (NSCLC), particularly in patients harbouring mutations in the EGFR gene. The echinoderm microtubule‑associated protein‑like 4‑anaplastic lymphoma kinase (EML4‑ALK) gene translocation has been described in a subset of patients with NSCLC and possesses potent oncogenic activity. This translocation represents one of the most novel molecular targets in the treatment of NSCLC. Patients who harbour the EML4‑ALK rearrangement possess lung tumours that lack EGFR or K‑ras mutations. The present study reports the case of a patient possessing the EML4‑ALK rearrangement that was initially treated with erlotinib and achieved a lasting clinical response. To the best of our knowledge, the current study is the first report of a clinical response to EGFR‑TKI in a patient with lung adenocarcinoma harbouring the EML4‑ALK fusion gene, but no EGFR mutations. However, as the disease progressed, the ALK gene status of the tumour was investigated, and based upon a positive result, the patient was treated with crizotinib and achieved a complete response. In conclusion, the present study suggests that the EML4‑ALK rearrangement is not always associated with resistance to EGFR‑TKIs. Further studies are required to clarify the biological features of these tumours and to investigate the mechanisms underlying the primary resistance to EGFR‑TKIs when the EML4‑ALK rearrangement is present.

View Figures

View References

1	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
2	Schiller JH, Harrington D, Belani CP, et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non small cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
3	Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
4	Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
5	Xu C, Zhou Q and Wu YL: Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis. J Hematol Oncol. 5:622012. View Article : Google Scholar : PubMed/NCBI
6	Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 290:2149–2158. 2003. View Article : Google Scholar : PubMed/NCBI
7	Solomon B, Varella-Garcia M and Camidge DR: ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol. 4:1450–1454. 2009. View Article : Google Scholar : PubMed/NCBI
8	Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 27:4247–4253. 2009. View Article : Google Scholar : PubMed/NCBI
9	Shaw AT and Solomon B: Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. 17:2081–2086. 2011. View Article : Google Scholar : PubMed/NCBI
10	Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
11	Shaw AT, Kim DW, Nakagawa K, et al: Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) (PROFILE 1007). Annal Oncol. 23(Suppl 9): ixe212012.
12	Koivunen JP, Mermel C, Zejnullahu K, et al: EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 14:4275–4283. 2008. View Article : Google Scholar : PubMed/NCBI
13	Kuo YW, Wu SG, Ho CC and Shih JY: Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol. 5:2039–2040. 2010. View Article : Google Scholar : PubMed/NCBI
14	Popat S, Vieira de Araújo A, Min T, et al: Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol. 6:1962–1963. 2011. View Article : Google Scholar : PubMed/NCBI
15	Santelmo C, Ravaioli A, Barzotti E, et al: Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib. Lung Cancer. 81:294–296. 2013. View Article : Google Scholar : PubMed/NCBI
16	Tiseo M, Gelsomino F, Boggiani D, et al: EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer. 71:241–243. 2011. View Article : Google Scholar
17	Tanaka H, Hayashi A, Morimoto T, et al: A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene. BMC Cancer. 12:5582012. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles